A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
National Institutes of Health Clinical Center (CC)
Aulos Bioscience, Inc.
3D Medicines
AstraZeneca
Mayo Clinic
Neonc Technologies, Inc.
Ocellaris Pharma, Inc.
Inhibrx Biosciences, Inc
CRISPR Therapeutics
ITM Oncologics GmbH
GI Innovation, Inc.
A2 Biotherapeutics Inc.
Incyte Corporation
NuCana plc
Medicenna Therapeutics, Inc.
Shanghai Public Health Clinical Center
OncoC4, Inc.
Kymab Limited
Portage Biotech
Sarcoma Oncology Research Center, LLC
University Hospital, Antwerp
GI Innovation, Inc.
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
GeneMedicine Co., Ltd.
Rain Oncology Inc
Klus Pharma Inc.
Genmab
City of Hope Medical Center
Western Sydney Local Health District
Nektar Therapeutics
Nektar Therapeutics
Institut Bergonié
Incyte Corporation
Faron Pharmaceuticals Ltd
Apollomics (Australia) Pty. Ltd.
Calithera Biosciences, Inc
Incyte Corporation
Gilead Sciences
Incyte Corporation
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Eli Lilly and Company
Mirror Biologics, Inc.
Shenzhen BinDeBio Ltd.
Celldex Therapeutics
Stanford University
Western Regional Medical Center
National Institutes of Health Clinical Center (CC)
Harbin Medical University